Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Gastrointestinal 1

Conditions

Breast Neoplasms 210Triple Negative Breast Neoplasms 32Stomach Neoplasms 30Inflammatory Breast Neoplasms 21Esophageal Neoplasms 15Carcinoma, Hepatocellular 15Lymphoma, Large B-Cell, Diffuse 9Sarcoma 8Neoplasms 8Non-Muscle Invasive Bladder Neoplasms 6Urinary Bladder Neoplasms 5Breast Neoplasms, Male 5Adenocarcinoma Of Esophagus 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Lymphoma 4Liver Neoplasms 4Testicular Neoplasms 3Primary Breast Cancer 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pathologic Complete Response 3Hemangiosarcoma 3Carcinoma, Ductal, Breast 3Unspecified Adult Solid Tumor, Protocol Specific 2Recurrence 2Prostatic Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplastic Cells, Circulating 2Neoplasms, Germ Cell and Embryonal 2

Interventions

Carboplatin 7Trastuzumab 6Docetaxel 5pembrolizumab 4Paclitaxel 4Oxaliplatin 4Fluorouracil 4Cytarabine 4Cyclophosphamide 4Azacitidine 4pertuzumab 3Radiotherapy 3Epirubicin 3Cisplatin 3Chemoradiotherapy 3Capecitabine 3venetoclax 2toripalimab 2sargramostim 2olaparib 2durvalumab 2cc-486 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Pemetrexed 2Observation 2Monatide (IMS 3015) 2Metformin 2Leucovorin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Pathologic Complete Response × Epirubicin × Clear all
NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Lund University Hospital

Phase 3 Active not recruiting
325 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Henan Cancer Hospital

Phase 3 Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

NCT01216644 2019-06-19

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Krankenhaus Nordwest

Phase 2/3 Completed
716 enrolled
Gastrointestinal

Pathologic Complete Response, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡